Safety Communication: Severe liver injury associated with the use of dronedarone (marketed as Multaq) 01-14-2011
The U.S. Food and Drug Administration (FDA) is alerting healthcare professionals and patients
about cases of rare, but severe liver injury, including two cases of acute liver failure leading to
liver transplant in patients treated with the heart medication dronedarone (Multaq).
Dronedarone is a drug used to treat abnormal heart rhythm in patients who have had an abnormal
heart rhythm (atrial fibrillation or atrial flutter) during the past 6 months. Dronedarone can
reduce the risk of being hospitalized for these heart problems. Since dronedarone's approval in
July 2009 through October 2010, around 492,000 dronedarone prescriptions were dispensed and around
147,000 patients filled dronedarone prescriptions at outpatient retail pharmacies in the United
States.1 Additional usage can occur in the hospital setting.
Dronedarone was approved
with a Risk Evaluation and Mitigation Strategy (REMS) with a goal of preventing its use in patients
with severe heart failure or who have recently been in the hospital for heart failure. In a study
of patients with these conditions, patients given dronedarone had a greater than two-fold increase
in risk of death.
Information about the potential risk of liver injury from
dronedarone is being added to the WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS sections of the
For more information, please visit: Multaq